Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2022

Open Access 01-12-2022 | Human Immunodeficiency Virus | Review

Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent

Authors: Mehdi Samadi, Vahid Salimi, Mohammad Reza Haghshenas, Seyed Mohammad Miri, Seyed Reza Mohebbi, Amir Ghaemi

Published in: Virology Journal | Issue 1/2022

Login to get access

Abstract

Background

Human pegivirus 1 (HPgV-1) is a Positive-sense single-stranded RNA (+ ssRNA) virus, discovered in 1995 as a Flaviviridae member, and the closest human virus linked to HCV. In comparison to HCV, HPgV-1 seems to be lymphotropic and connected to the viral group that infects T and B lymphocytes. HPgV-1 infection is not persuasively correlated to any known human disease; nevertheless, multiple studies have reported a connection between chronic HPgV-1 infection and improved survival in HPgV-1/HIV co-infected patients with a delayed and favorable impact on HIV infection development. While the process has not been thoroughly clarified, different mechanisms for these observations have been proposed. HPgV-1 is categorized into seven genotypes and various subtypes. Infection with HPgV-1 is relatively common globally. It can be transferred parenterally, sexually, and through vertical ways, and thereby its co-infection with HIV and HCV is common. In most cases, the clearance of HPgV-1 from the body can be achieved by developing E2 antibodies after infection.

Main body

In this review, we thoroughly discuss the current knowledge and recent advances in understanding distinct epidemiological, molecular, and clinical aspects of HPgV-1.

Conclusion

Due to the unique characteristics of the HPgV-1, so advanced research on HPgV-1, particularly in light of HIV co-infection and other diseases, should be conducted to explore the essential mechanisms of HIV clearance and other viruses and thereby suggest novel strategies for viral therapy in the future.
Literature
1.
Deinhardt F, Holmes AW, Capps RB, Popper H. studies on the transmission of human viral hepatitis to marmoset monkeys. Transmission of disease, serial passages and description of liver lesions (1967).
2.
Gust ID, Feinstone SM. Hepatitis A. Boca Raton: CRC Press; 1988. p. 2.
3.
Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, Muerhoff AS, Erker JC, Buijk SL, Chalmers ML. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci. 1995;92(8):3401–5.PubMedPubMedCentral
4.
Muerhoff AS, Leary TP, Simons JN, Pilot-Matias TJ, Dawson GJ, Erker JC, Chalmers ML, Schlauder GG, Desai SM, Mushahwar IK. Genomic organization of GB viruses A and B: two new members of the flaviviridae associated with GB Agent hepatitis. J Virol. 1995;69(9):5621–30.PubMedPubMedCentral
5.
Linnen J, Wages J, Zhang-Keck Z-Y, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Yoshiyuki Nakatsuji J, Shih W-K, Young L, Piatak M, Hoover C, Fernandez J, Chen S, Zou J-C, Morris T, Hyams KC, Ismay S, Lifson JD, Hess G, Foung SKH, Thomas H, Bradley D, Margolis H, Kim JP. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science. 1996;271:505–8.PubMed
6.
Epstein JH, Quan PL, Briese T, Street C, Jabado O, Conlan S, et al. Identification of GBV-D, a novel GB-like flavivirus from old world frugivorous bats (Pteropus giganteus) in Bangladesh. PLoS Pathog. 2010;6:e1000972.PubMedPubMedCentral
7.
Bukh J, Apgar CL, Yanagi M. Toward a surrogate model for hepatitis C virus: an infectious molecular clone of the GB virus-B hepatitis agent. Virology. 1999;262:470–8.PubMed
8.
Nam JH, Faulk K, Engle RE, Govindarajan S, St Claire M, Bukh J. In vivo analysis of the 3’ untranslated region of GB virus B after in vitro mutagenesis of an infectious cDNA clone: persistent infection in a transfected tamarin. J Virol. 2004;78(17):9389–99.PubMedPubMedCentral
9.
Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol. 2011;92(Pt 2):233–46.PubMedPubMedCentral
10.
Berg MG, Lee D, Coller K, Frankel M, Aronsohn A, Cheng K, et al. Discovery of a novel human pegivirus in blood associated with hepatitis C virus co-infection. PLoS Pathog. 2015;11(12):e1005325.PubMedPubMedCentral
11.
Kapoor A, Kumar A, Simmonds P, Bhuva N, Singh Chauhan L, Lee B, et al. Virome analysis of transfusion recipients reveals a novel human virus that shares genomic features with hepaciviruses and pegiviruses. MBio. 2015;6(5):e01466-15.PubMedPubMedCentral
12.
Bonsall D, Gregory WF, Ip CL, Donfield S, Iles J, et al. Evaluation of viremia frequencies of a novel human pegivirus by using bioinformatic screening and PCR. Emerg Infect Dis. 2016;22(4):671–8.PubMedPubMedCentral
13.
Ramezani A, Banifazl M, Aghakhani A. GB virus C overview: insights into clinical implication. J GHR. 2013;2(1):343–9.
14.
Fukushi S, Kurihara C, Ishiyama N, Okamura H, Hoshino FB, Oya A, et al. Nucleotide sequence of the 5 noncoding region of hepatitis G virus isolated from Japanese patients: comparison with reported isolates. Biochem Biophys Res Commun. 1996;226(2):314–8.PubMed
15.
Muerhoff AS, Simons JN, Leary TP, Erker JC, Chalmers ML, Pilot-Matias TJ, Dawson GJ, Desai SM, Mushahwar IK. Sequence heterogeneity within the S-terminal region of the hepatitis GB virus C genome and evidence for genotypes. J Hepatol. 1996;25:379–84.PubMed
16.
Feng Y, Zhao W, Feng Y, Dai J, Li Z, Zhang X, et al. A novel genotype of GB virus C: its identification and predominance among injecting drug users in Yunnan, China. PLoS ONE. 2011;6(10):e21151.PubMedPubMedCentral
17.
Ruiz V, Giordano M, Rivero CW, Minassian ML, Cuestas ML, Trinks J, et al. GB virus C quasispecies detected in plasma and lymphocyte subsets in a natural human infection. J Gen Virol. 2010;91(7):1687–92.PubMed
18.
Stapleton JT. GB virus type C/hepatitis G virus. Semin Liver Dis. 2003;23(2):137–48.PubMed
19.
Zhang W, Chaloner K, Tillmann HL, Williams CF, Stapleton JT. Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV Med. 2006;7:173–80.PubMed
20.
Vahidnia F, Petersen M, Stapleton JT, Rutherford GW, Busch M, Custer B. Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis. 2012;55(7):1012–9.PubMedPubMedCentral
21.
Lauck M, Bailey AL, Andersen KG, Goldberg TL, Sabeti PC, O’Connor DH. GB virus C coinfections in west African Ebola patients. J Virol. 2015;89(4):2425–9.PubMed
22.
23.
Kleinman S, Hepatitis G. Virus biology, epidemiology, and clinical manifestations: implications for blood safety. Transfus Med Rev. 2001;15(3):201–12.PubMed
24.
25.
Ramezani A, Gachkar L, Eslamifar A, Khoshbaten M, Jalilvand S, Adibi L, et al. Detection of hepatitis G virus envelope protein E2 antibody in blood donors. Int J Infect Dis. 2008;12(1):57–61.PubMed
26.
Schlauder GG, Dawson GJ, Simons JN, Pilot-Matias TJ, Gutierrez RA, Heynen CA, Knigge MF, Kurpiewski GS, Buijk SL, Leary TP, Muerhoff AS. Molecular and serologic analysis in the transmission of the GB hepatitis agents. J Med Virol. 1995;46:4681–90.
27.
Chivero ET, Stapleton JT. Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection. J Gen Virol. 2015;96(Pt 7):1521–32.PubMed
28.
Leary TP, Muerhoff S, Simons JN, Pilot-Matias TJ, Erker JC, Chalmers ML, Schalauder GG, Dawson GJ, Desai SM, Mushahwar IK. Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. J Med Virol. 1996;48(1):60–7.PubMed
29.
Kim JP, Fry KE. Molecular characterization of the hepatitis G virus. J Viral Hepat. 1997;4:77–9.PubMed
30.
31.
Martin A, Bodola F, Sangar DV, Goettge K, Popov V, Rijnbrand R, et al. Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA. PNAS. 2003;100(17):9962–7.PubMedPubMedCentral
32.
Bukh J, Apgar CL. Five new or recently discovered (GBV-A) virus species are indigenous to new world monkeys and may constitute a separate genus of the flaviviridae. Virology. 1997;229:429–36.PubMed
33.
Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. J Gen Virol. 2016;97(11):2894–907.PubMedPubMedCentral
34.
Forberg K, Rodgers MA, Dawson GJ, Sauleda S, Olivo A, Vallari A, et al. Human pegivirus 2 exhibits minimal geographic and temporal genetic diversity. Virology. 2020;539:69–79.PubMed
35.
Hyland CA, Mison L, Solomon N, Cockerill J, Wang L, Hunt J, Selvey LA, Faoagali J, Cooksley WG, Young IF, Trowbridge R, Borthwick I, Gowans EJ. Exposure to GB virus type C or hepatitis G virus in selected Australian adult and children populations. Transfusion. 1998;38:821–7.PubMed
36.
37.
Pilot-Matias TJ, Carrick RJ, Coleman PF, Leary TP, Surowy TK, Simons JN, et al. Expression of the GB Virus C E2 glycoprotein using the semliki forest virus vector system and its utility as a serologic marker. Virology. 1996;225:282–92.PubMed
38.
Gutierrez RA, Dawson GJ, Knigge MF, Melvin SL, Heynen CA, Kyrk CR, et al. Seroprevalence of GB virus C and persistence of RNA and antibody. J Med Virol. 1997;53:167–73.PubMed
39.
Blair CS, Davidson F, Lycett C, McDonald DM, Haydon GH, Yap PL, Hayes PC, Simmonds P, Gillon J. Prevalence, incidence, and clinical characteristics of hepatitis G virus/GB virus C infection in scottish blood donors. J Infect Dis. 1998;178:1779–82.PubMed
40.
Tucker TJ, Louw SJ, Robson SC, Isaacs S, Kirsch RE. High prevalence of GBV-C hepatitis G virus infection in a rural South African population. J Med Virol. 1997;53:225–8.PubMed
41.
Ren F-R, Wang Y, Li H. Hepatitia G virus infection in screened chinese blood donors. Vox Sang. 1998;74:51–2.PubMed
42.
El-Zayadi AR, Abe K, Selim O, Naito H, Hess G, Ahdy A. Prevalence of GBV-C: hepatitis G virus viraemia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. J Virol Methods. 1999;80:53–8.PubMed
43.
Slavov SN, Silveira RM, Rodrigues ES, Diefenbach CF, Zimmermann AM, Covas DT, et al. Human pegivirus-1 (HPgV-1, GBV-C) RNA prevalence and genotype diversity among volunteer blood donors from an intra-hospital hemotherapy service in Southern Brazil. Transfus Apher Sci. 2019;58(2):174–8.PubMed
44.
Lefrere JJ, Loiseau P, Maury J, Lasserre J, Mariotti M, Ravera N, Lerable J, Lefèvre G, Morand-Joubert L, Girot R. Natural history of GBV-C/hepatitis G virus infection through the follow-up of GBV-C/hepatitis G virus–infected blood donors and recipients studied by RNA polymerase chain reaction and anti-E2 serology. Blood J Am Soc Hematol. 1997;90(9):3776–80.
45.
Agi E, Hojjatipour S, Namvar A, Bolhassani A. Impact of blood transfusion on the prevalence of HHpgV-1, HPgV-1, and B19V among Iranian HCV-infected patients with hemophilia. J Pediatr Hematol Oncol. 2020;42(4):e213–8.PubMed
46.
Singh S, Blackard JT. Human pegivirus (HPgV) infection in sub-Saharan Africa-a call for a renewed research agenda. Rev Med Virol. 2017;27(6):e1951.
47.
48.
Pessoa MG, Terrault NA, Detmer J, Kolberg J, Collins M, Hassoba HM, Wright TL. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatol Res. 1998;27(3):877–9.
49.
Seifried C, Weber M, Bialleck H, Seifried E, Schrezenmeier H, Kurt Roth W. High prevalence of GBV-C/HGV among relatives of GBV-C/HGV-positive blood donors in blood recipients and in patients with aplastic anemia. Transfusion. 2004;44:268–74.PubMed
50.
Frey SE, Musial CE, Homan SM, Sokol-Anderson M, Di Bisceglie A, Cayco MT, et al. Evidence for probable sexual transmission of the hepatitis G virus. Clin Infect Dis. 2002;34:1033–8.PubMed
51.
Heinz-Jurgen T, Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. 7th ed. Philadelphia: Wolters Kluwer; 2020. p. 758–928.
52.
Simons JN, Desai SM, Schultz DE, Lemon SM, Mushahwar IK. Translation initiation in GB viruses A and C: evidence for internal ribosome entry and implications for genome organization. J Virol. 1996;70(9):6126–35.PubMedPubMedCentral
53.
Xiang J, Wünschmann S, Schmidt W, Shao J, Stapleton JT, Dawson GJ. Full-length GB virus C (hepatitis G virus) RNA Transcripts are infectious in primary CD4-positive T cells. J Virol. 2000;74:9125–33.PubMedPubMedCentral
54.
Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology. 2004;39(1):5–19.PubMed
55.
Melvin SL, Dawson GJ, Carrick RJ, Schlauder GG, Heynen CA, Mushahwar IK. Biophysical characterization of GB virus C from human plasm. J Virol Methods. 1998;71:147–57.PubMed
56.
Xiang J, Klinzman D, McLinden J, Schmidt WN, LaBrecque DR, Gish R, Stapleton JT. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol. 1998;27(4):2738–44.
57.
Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol. 2007;81(1):374–83.PubMed
58.
Hassoba HM, Pessoa MG, Terrault NA, Lewis NJ, Hayden M, Hunt JC, et al. Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. J Med Virol. 1998;56:253–8.PubMed
59.
Tillmann HL, Heringlake S, Trautwein C, Meissner D, Nashan B, Schlitt HJ, Kratochvil J, Hunt J, Qiu X, Lou SC, Pichlmayr R. Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatol Res. 1998;28(2):379–84.
60.
Agnello V, Abel G, Elfahal M, Knight GB, Zhang Q-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci. 1999;96(22):12766–71.PubMedPubMedCentral
61.
Kapoor A, Simmonds P, Cullen JM, Scheel TKH, Medina JL, Giannitti F, et al. Identification of a pegivirus (GB virus-like virus) that infects horses. J Virol. 2013;87(12):7185–90.PubMedPubMedCentral
62.
Quan P-L, Firth C, Conte JM, Williams SH, Zambrana-Torrelio CM, Anthony SJ, et al. Bats are a major natural reservoir for hepaciviruses and pegiviruses. PNAS. 2013;110(20):8194–9.PubMedPubMedCentral
63.
Gwack Y, Yoo H, Song I, Choe J, Han JH. RNA-stimulated ATPase and RNA helicase activities and RNA binding domain of hepatitis G virus nonstructural protein 3. J Virol. 1999;73(4):2909–15.PubMedPubMedCentral
64.
Zhong W, Ingravallo P, Wright-Minogue J, Skelton A, Uss AS, Chase R, Yao N, Lau JY, Hong Z. Nucleoside triphosphatase and RNA helicase activities associated with GB Virus B nonstructural protein 3. Virology. 1999;261:216–26.PubMed
65.
Ghai RR, Sibley SD, Lauck M, Dinis JM, Bailey AL, Chapman CA, et al. Deep sequencing identifies two genotypes and high viral genetic diversity of human pegivirus (GB virus C) in rural Ugandan patients. J Gener Virol. 2013;94(Pt 12):2670–8.
66.
Li Z, Li Y, Liang Y, Hu L, Chen S. Prevalence and risk factors of human pegivirus type 1 infection in hematopoietic stem cell transplantation patients. Int J Infect Dis. 2019;85:111–3.PubMed
67.
Blackard JT, Ma G, Welge JA, King CC, Taylor LE, Mayer KH, et al. GB virus C (GBV-C) infection in hepatitis C virus (HCV) seropositive women with or at risk for HIV infection. PLoS ONE. 2014;9(12):e114467.PubMedPubMedCentral
68.
N’Guessan KF, Boyce C, Kwara A, Archampong TNA, Lartey M, Sagoe KW, et al. Human pegivirus (HPgV) infection in Ghanaians co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Virus Genes. 2018;54(3):361–7.PubMedPubMedCentral
69.
Hosseini-Moghaddam SM, Keyvani H, Samadi M, Alavian SM, Mahdavimazdeh M, Daneshvar S, et al. GB virus type C infection in hemodialysis patients considering co-infection with hepatitis C virus. J Med Virol. 2008;80(7):1260–3.PubMed
70.
Mehdi S, Keyvani H, Moghaddam SMH. Prevalence and risk factors of the hepatitis G (HGV) infection in hemodialysis patients. Iran J Clin Infect Dis. 2008;3(1):7–11.
71.
72.
Miao Z, Gao L, Song Y, Yang M, Zhang M, Lou J, et al. Prevalence and clinical impact of human pegivirus-1 infection in HIV-1-infected individuals in Yunnan, China. Viruses. 2017;9(2):28.PubMedCentral
73.
Muerhoff AS, Leary TP, Sathar MA, Dawson GJ, Desai SM. African origin of GB virus C determined by phylogenetic analysis of a complete genotype 5 genome from South Africa. J Gen Virol. 2005;86(Pt 6):1729–35.PubMed
74.
Tri Rinonce H, Yano Y, Utsumi T, Heriyanto DS, Anggorowati N, Widasari DI, et al. Prevalence and genotypic distribution of GB virus C and torque teno virus among patients undergoing hemodialysis. Mol Med Rep. 2017;15(5):2843–52.
75.
Fan X, Xu Y, Detre K, Di Bisceglie AM. Direct evidence for GB virus C/hepatitis G virus (GBV-C/HGV) superinfection: elimination of resident viral strain by donor strain in a patient undergoing liver transplantation. J Med Virol. 2002;68(1):76–81.PubMed
76.
Wu H, Padhi A, Xu J, Gong X, Tien P. Evidence for within-host genetic recombination among the human pegiviral strains in HIV infected subjects. PLoS ONE. 2016;11(8):e0161880.PubMedPubMedCentral
77.
Xiang J, Martinez-Smith C, Gale M Jr, Chang Q, Labrecque DR, Schmidt WN, et al. GB virus type C NS5A sequence polymorphisms: association with interferon susceptibility and inhibition of PKR-mediated eIF2alpha phosphorylation. J Interferon Cytokine Res. 2005;25(5):261–70.PubMed
78.
Jordier F, Deligny ML, Barré R, Robert C, Galicher V, Uch R, Fournier PE, Raoult D, Biagini P. Human pegivirus isolates characterized by deep sequencing from hepatitis C virus-RNA and human immuno deficiency virus-RNA–positive blood donations. France J Med Virol. 2021;91(1):38–44.
79.
Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis. 2002;34:1108–14.PubMed
80.
Schwarze-Zander C, Blackard JT, Rockstroh JK. Role of GB virus C in modulating HIV disease. Expert Rev Anti-Infect Ther. 2012;10(5):563–72.PubMedPubMedCentral
81.
Ruegamer T, Hoffmann R, Rohrhofer A, Audebert F, Salzberger B, Korn K, et al. Inhibition of HIV-1 infection by human pegivirus type 1-derived peptides is affected by human pegivirus type 1 genotype and HIV-1 coreceptor tropism. AIDS. 2018;32(14):1951–7.PubMed
82.
Mohr EL, Stapleton JT. GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat. 2009;16(11):757–68.PubMedPubMedCentral
83.
Horemheb-Rubio G, Ramos-Cervantes P, Arroyo-Figueroa H, Ávila-Ríos S, García-Morales C, Reyes-Terán G, et al. High HPgV replication is associated with improved surrogate markers of HIV progression. PLoS ONE. 2017;12(9):e0184494.PubMedPubMedCentral
84.
Chivero ET, Bhattarai N, Rydze RT, Winters MA, Holodniy M, Stapleton JT. Human pegivirus RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA-containing particles are infectious in vitro. J Gen Virol. 2014;95(6):1307–19.PubMedPubMedCentral
85.
Fama A, Larson MC, Link BK, Habermann TM, Feldman AL, Call TG, et al. Human pegivirus infection and lymphoma risk: a systematic review and meta-analysis. Clin Infect Dis. 2020;71(5):1221–8.PubMed
86.
Leyssen P, De Clercq E, Neyts J. Perspectives for the treatment of infections with flaviviridae. Clin Microbiol Rev. 2000;13(1):67–82.PubMedPubMedCentral
87.
Balcom EF, Doan MAL, Branton WG, Jovel J, Blevins G, Edguer B, et al. Human pegivirus-1 associated leukoencephalitis: clinical and molecular features. Ann Neurol. 2018;84(5):781–7.PubMed
88.
Bukowska-Ośko I, Perlejewski K, Pawełczyk A, Rydzanicz M, Pollak A, Popiel M, et al. Human pegivirus in patients with encephalitis of unclear etiology, Poland. Emerg Infect Dis. 2018;24(10):1785–94.PubMedPubMedCentral
89.
Tuddenham R, Eden J-S, Gilbey T, Dwyer DE, Jennings Z, Holmes EC, et al. Human pegivirus in brain tissue of a patient with encephalitis. Diagn Microbiol Infect Dis. 2020;96(2):114898.PubMed
90.
Williams CF, Klinzman D, Yamashita TE, Xiang J, Polgreen PM, Rinaldo C, Liu C, Phair J, Margolick JB, Zdunek D, Hess G. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med. 2004;350:981–90.PubMed
91.
Souza Carolynne RGK, Jason T, Kenneth ES, Hui Z, Dietmar Z, et al. GB Virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV–coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis. 2006;194:410–9.
92.
Rodríguez AK, Garzaro DJ, Loureiro CL, Gutiérrez CR, Ameli G, Jaspe RC, et al. HIV-1 and GBV-C co-infection in Venezuela. J Infect Dev Ctries. 2014;8(7):863–8.PubMed
93.
Heringlake S, Ockenga J, Tillmann HL, Trautwein C, Meissner D, Stoll M, Hunt J, Jou C, Solomon N, Schmidt RE, Manns MP. GB virus C/hepatitis G virus infection: A favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis. 1998;177:1723–6.PubMed
94.
Supapol WB, Remis RS, Raboud J, Millson M, Tappero J, Kaul R, et al. Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection. J Infect Dis. 2008;197(10):1369–77.PubMed
95.
Muerhoff AS, Tillmann HL, Manns MP, Dawson GJ, Desai SM. GB virus C genotype determination in GB virus-C/HIV co-infected individuals. J Med Virol. 2003;70(1):141–9.PubMed
96.
Mota LDD, Finger-Jardim F, Silva CM, Germano FN, Nader MM, Gonçalves CV, et al. Molecular and clinical profiles of human pegivirus type 1 infection in individuals living with HIV-1 in the extreme South of Brazil. BioMed Res Int. 2019;2019:1–11.
97.
Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL. TH1 and TH2 cytokine production by pripheral blood mononuclear cells from HIV infected patients. AIDS. 1994;8:757–62.PubMed
98.
Rydze RT, Xiang J, McLinden JH, Stapleton JT. GB virus type C infection polarizes T-cell cytokine gene expression toward a Th1 cytokine profile via NS5A protein expression. J Infect Dis. 2012;206(1):69–72.PubMedPubMedCentral
99.
Chang Q, McLinden JH, Stapleton JT, Sathar MA, Xiang J. Expression of GB virus C NS5A protein from genotypes 1, 2, 3 and 5 and a 30 aa NS5A fragment inhibit human immunodeficiency virus type 1 replication in a CD4+ T-lymphocyte cell line. J Gen Virol. 2007;88(12):3341–6.PubMed
100.
Xiang J, McLinden JH, Chang Q, Jordan EL, Stapleton JT. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication. PLoS ONE. 2008;3(7):e2580.PubMedPubMedCentral
101.
Xiang J, McLinden JH, Rydze RA, Chang Q, Kaufman TM, Klinzman D, et al. Viruses within the flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+cells. J Immunol. 2009;183(12):7860–9.PubMed
102.
Lalle E, Sacchi A, Abbate I, Vitale A, Martini F, D’Offiz G, Antonucci G, Castilletti C, Poccia F, Capobianchi MR. Activation of interferon response genes and of plasmacytoid dendritic cells in HIV-1 positive subjects with GB virus C co-infection. Int J Immunopathol Pharmacol. 2008;21(1):161–71.PubMed
103.
Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 2001;22(6):312–6.PubMed
104.
Jung S, Knauer O, Donhauser N, Eichenmüller M, Helm M, Fleckenstein B, Reil H. Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS. 2005;19:1267–72.PubMed
105.
Haoming W, Tien P, Gong X. Phylogenetic diversity of GB virus C at the antigenic site of E2 protein. Virus Res. 2013;178(2):502–5.
106.
Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, et al. Definition of an 18-mer synthetic peptide derived from the GB virus C E1 protein as a new HIV-1 entry inhibitor. Biochim Biophys Acta Gen Subj. 2016;1860(6):1139–48.
107.
Pérez Y, Gómara MJ, Yuste E, Gómez-Gutierrez P, Pérez JJ, Haro I. Structural study of a new HIV-1 entry inhibitor and interaction with the HIV-1 fusion peptide in dodecylphosphocholine micelles. Chem A Eur J. 2017;23(48):11703–13.
108.
109.
Hoffmann R, Ruegamer T, Schaubächer J, Rohrhofer A, Kirmeß P, Fiebig KM, et al. Exploring viral interference using peptides: molecular determinants of HIV-1 inhibition by a peptide derived from human pegivirus-1 envelope protein E2. ChemMedChem. 2021;16(8):1290–6.PubMedPubMedCentral
110.
Maidana-Giret MT, Silva TM, Sauer MM, Tomiyama H, Levi JE, Bassichetto KC, et al. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS. 2009;23(17):2277–87.PubMed
111.
Mohr EL, Xiang J, McLinden JH, Kaufman TM, Chang Q, Montefiori DC, et al. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J Immunol. 2010;185(7):4496–505.PubMed
112.
George SL, Varmaz D, Tavis JE, Chowdhury A. The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+T lymphocyte cell line without decreasing HIV receptor expression. PLoS ONE. 2012;7(1):53.
113.
Hofer H, Aydin I, Neumueller-Guber S, Mueller C, Scherzer TM, Staufer K, et al. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy. J Viral Hepat. 2010;18(7):513–7.PubMed
114.
Boodram B, Hershow RC, Klinzman D, Stapleton JT. GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection. J Viral Hepat. 2011;18(4):e153–9.PubMedPubMedCentral
115.
Davod J, Manoochehr M, Eskandar H, Davod K, Ali Reza SZ. Hepatitis G virus and its prevalence and genotypes in patients with hepatitis B and C in Ahvaz, southwestern Iran. Turk J Med Sci. 2013;43(3):474–8.
116.
Tedaldi EM, Wood KC, Baker RK, Moorman AC, Holmberg SD, Alzola CF, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;36:363–7.PubMed
117.
Puoti M, Putzolu V, Zaltron S, Bonacini M, Callea F, Gargiulo F, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis. 2001;183:134–7.PubMed
118.
Pineda JA, Macias J. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrob Chemother. 2005;55(4):417–9.PubMed
119.
Yu ML, Lin ZY, Chuang WL, Hsieh MY, Chang WY, et al. GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-therapy. Antiviral Res. 2001;52:241–9.PubMed
120.
Barbosa AD, Baggio-Zappia GL, Dobo C, Alves-Sousa VK, Lanzara GD, Silva ID, Lanzoni VP, Granato CF. Analysis of GB virus C infection among HIV-HCV coinfected patients. Rev Soc Bras Med Trop. 2009;42(5):591–3.
121.
Wan Z, Liu J, Hu F, Shui J, Li L, Wang H, et al. Evidence that the second human pegivirus (HPgV-2) is primarily a lymphotropic virus and can replicate independent of HCV replication. Emerg Microb Infect. 2020;9(1):485–95.
122.
Wang H, Wan Z, Sun Q, Zhu N, Li T, Ren X, An X, Deng S, Wu Y, Li X, Li L. Second human pegivirus in hepatitis C virus-infected and hepatitis C virus/HIV-1–co-infected persons who inject drugs, China. Emerg Infect Dis. 2018;24(5):908.PubMedPubMedCentral
123.
Coller KE, Berg MG, Frankel M, Forberg K, Surani R, Chiu CY, et al. Antibodies to the novel human pegivirus 2 are associated with active and resolved infections. J Clin Microbiol. 2016;54(8):2023–30.PubMedPubMedCentral
124.
Tanaka E, Kiyosawa K, Shimoda K, Hino K, Tacke M, Schmolke S, et al. Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis. J Viral Hepat. 1998;5:153–9.PubMed
125.
126.
Berg T, Müller AR, Platz KP, Höhne M, Bechstein WO, Hopf U, Wiedenmann B, Neuhaus P, Schreier E. Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology. 1999;29(1):245–9.PubMed
127.
Mushahwar IK, Zuckerman JN. Clinical implications of GB virus C. J Med Virol. 1998;56:1–3.PubMed
128.
Bhanich Supapol W, Remis RS, Raboud J, Millson M, Tappero J, Kaul R, et al. Prevalence and correlates of GB virus C infection in HIV-infected and HIV-uninfected pregnant women in Bangkok, Thailand. J Med Virol. 2011;83(1):33–44.PubMed
129.
Chen HL, Chang MH, Lin HH, Ni YH, Hsu HY, Wang JT, Chen DS. Antibodies to E2 protein of hepatitis G virus in children: different responses according to age at infection. J Pediatr. 1998;133(3):382–5.PubMed
130.
Polgreen PM, Xiang J, Chang Q, Stapleton JT. GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals. Microb Infect. 2003;5(13):1255–61.
131.
Gomara MJ, Fernandez L, Perez T, Ercilla G, Haro I. Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection. Anal Biochem. 2010;396(1):51–8.PubMed
132.
Gomara MJ, Fernandez L, Perez T, Tenckhoff S, Casanovas A, Tillmann HL, et al. Diagnostic value of anti-GBV-C antibodies in HIV-infected patients. Chem Biol Drug Des. 2011;78(2):277–82.PubMed
133.
Metadata
Title
Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent
Authors
Mehdi Samadi
Vahid Salimi
Mohammad Reza Haghshenas
Seyed Mohammad Miri
Seyed Reza Mohebbi
Amir Ghaemi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2022
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-022-01769-3

Other articles of this Issue 1/2022

Virology Journal 1/2022 Go to the issue

Correction

Correction to: Deep sequencing of the HIV-1 polymerase gene for characterisation of cytotoxic T-lymphocyte epitopes during early and chronic disease stages

Research

A fast extraction-free isothermal LAMP assay for detection of SARS-CoV-2 with potential use in resource-limited settings

Research

Transcriptional differences between coronavirus disease 2019 and bacterial sepsis

Research

Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models

Review

Application of machine learning in understanding plant virus pathogenesis: trends and perspectives on emergence, diagnosis, host-virus interplay and management

Research

SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits